Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S.

被引：0
|
作者：
Thomas Abrams
Lisa M. Hess
Yajun Emily Zhu
William Schelman
Astra M. Liepa
Charles Fuchs
机构：
[1] Harvard Medical School,Dana
[2] Corporate Center,Farber Cancer Institute
[3] US Medical Affairs,Eli Lilly and Company, Global Patient Outcomes and Real World Evidence
[4] Yale Cancer Center,Eli Lilly and Company
来源：
Gastric Cancer | 2018年 / 21卷
关键词：
Population characteristics; Stomach neoplasms; Drug therapy; Antineoplastic agents;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：738 / 744
页数：6
相关论文
共 50 条
  • [41] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    van Meerten, E.
    Eskens, F. A. L. M.
    van Gameren, E. C.
    Doorn, L.
    van der Gaast, A.
    BRITISH JOURNAL OF CANCER, 2007, 96 (09) : 1348 - 1352
  • [42] A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer
    Haiping Jiang
    Jiong Qian
    Peng Zhao
    Xiaochen Zhang
    Yi Zheng
    Chenyu Mao
    Yulong Zheng
    Linghong Chen
    Yao Wang
    Haibo Mou
    Weijia Fang
    Lisong Teng
    Nong Xu
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 197 - 203
  • [43] A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer
    Jiang, Haiping
    Qian, Jiong
    Zhao, Peng
    Zhang, Xiaochen
    Zheng, Yi
    Mao, Chenyu
    Zheng, Yulong
    Chen, Linghong
    Wang, Yao
    Mou, Haibo
    Fang, Weijia
    Teng, Lisong
    Xu, Nong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 197 - 203
  • [44] Pretreatment Heterogeneity Predicts Treatment Outcome Of First-line Chemotherapy In Patients With Metastatic Triple Negative Breast Cancer
    Gong, C.
    Ma, G.
    Hu, X.
    Zhang, Y.
    Wang, Z.
    Zhang, J.
    Zhao, Y.
    Li, Y.
    Xie, Y.
    Yang, Z.
    Wang, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S458 - S459
  • [45] Three-Weekly S-1 Monotherapy as First-Line Treatment in Elderly Patients with Recurrent or Metastatic Gastric Cancer
    Lim, Joo Han
    Lee, Moon Hee
    Kim, Hyung Gil
    Shin, Yong Woon
    Yi, Hyeon Gyu
    Shin, Seok Hwan
    Hur, Yoon Seok
    Kim, Chul Soo
    Chang, Hye Jeong
    GUT AND LIVER, 2010, 4 (04) : 503 - 507
  • [46] Pharmacogenetic Angiogenesis Profiling for First-Line Chemotherapy in Patients With Advanced Gastric Cancer
    Su Dan
    Li Bai
    Wang Li-Jie
    Zhang Ting
    Mao Zhi-Yuan
    CANCER INVESTIGATION, 2013, 31 (06) : 390 - 396
  • [47] Exposure and clearance of bevacizumab in patients with first-line advanced gastric cancer.
    Sersch, Martina A.
    Han, Kelong
    Maia, Mauricio
    Jin, Jin
    Allison, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China
    Xiao, Cheng
    Qian, Jiong
    Zheng, Yulong
    Song, Fang
    Wang, Qiangfeng
    Jiang, Haiping
    Mao, Chenyu
    Xu, Nong
    MEDICINE, 2019, 98 (20)
  • [49] Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
    Liu, Mengyao
    Hu, Guofang
    Wang, Yuan
    Guo, Jun
    Liu, Liyan
    Han, Xiao
    Wang, Zhehai
    ONCOTARGETS AND THERAPY, 2018, 11 : 375 - 381
  • [50] Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer
    Min, YJ
    Bang, SJ
    Shin, JW
    Kim, DH
    Park, JH
    Kim, GY
    Ko, BK
    Choi, DH
    Cho, HR
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2004, 19 (03) : 369 - 373
12345